Comparison of Pig,Human and Rat Hepatocytes as a Source of Liver Specific Metabolic Functions in Culture Systems - Implications for Use in Bioartificial Liver Devices
Restricted accessResearch articleFirst published online June, 2001
Comparison of Pig,Human and Rat Hepatocytes as a Source of Liver Specific Metabolic Functions in Culture Systems - Implications for Use in Bioartificial Liver Devices
The limited availability of human hepatocytes results in the use of animal cells in most bioartificial liver support devices. In the present work, clinically relevant liver specific metabolic activities were compared in rat, pig and human hepatocytes cultured on liver-derived biomatrix to optimize the expression of differentiated functions. Pig hepatocytes showed higher rates of diazepam metabolism (2.549±0.821 μg/h/million cells vs. 0.474±0.079 μg/h/million cells rats, p<0.005, and vs. 0.704±0.171 μg/h/million cells in man, p<0.005) and of bilirubin conjugation (21.60116±8.433237 μmoles/l/24 h vs. 6.786809±2.983758 in man, p<0.001 and vs. 9.956538±1.781016 μmoles/l/24 h in rats, p<0.005). Urea synthesis was similar in pig and in human hepatocytes (150±46.3 vs. 144.8±21.46 nmoles/h/million cells) and it was lower in rats (84.38±35.2; p<0.001 vs. man, p<0.02 vs. pig). High liver specific metabolic activities in cultured pig hepatocytes further support their use as a substitue for human cells in bioartificial liver devices
McGuireB.M., SielaffT.D., NybergS.L., HuM.Y., CerraF.B., BloomerJ.R.. Review of support systems used in the managament of fulminant hepatic failure.Dig Dis1995; 13: 379–88.
2.
ChenS., EguchiS., WatanabeF.. Hepatic support strategies.Transplant Proc1996; 28: 2036–8.
WatanabeF.D., MullonC.J.P., HewittW.R.. Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial.Ann Surg1997; 225: 484–94.
5.
NybergS.L., MisraP.. Hepatocyte liver assist system - a clinical update.Mayo Clin Proc1998; 73: 765–71.
BisselD.M.. Artificial liver: the biological core. In: CrepaldiG., DemetriouA.A., MuracaM., eds. Bioartificial liver support systems - the critical issues.Rome: CIC International Editions, 1997; 55–61.
8.
MorsianiE., RozgaJ., ScottH.C.. Automated liver cell processing facilitates large scale isolation and purification of porcine hepatocytes.ASAIO J1995; 41: 155–61.
9.
DonatoM.T., CastellJ.V., Gomez-LechonM.J.. Characterization of drug metabolizing activities in pig hepatocytes for use in bioartificial liver devices: comparison with other hepatic cellular models.J Hepatol1999; 31: 42–9.
10.
GerlachJ., SchnoyN., SmithM.D., NeuhausP.. Hepatocyte culture between woven capillary networks: a microscopy study.Int J Artif Organs1994; 18(3): 226–30.
11.
TsiaoussisJ., NewsomeP.N., NelsonL.J., HayesP.C., PlevrisJ.N.. Which hepatocyte will it be? Hepatocyte choice for bioartificial liver support systems.Liver Transplant2001: 7: 2–10.
12.
JareguiH.O., NgS-F, GannK.L., WaxmanD.J.. Xenobiotic induction of P-450 PB-4 (IIB1) and P-450c (IA1) and associated monooxygenase activities in primary cultures of adult rat hepatocytes.Xenobiotica1991; 21: 1091–106.
13.
NybergS.L., MannH.J., RemmelR.P., HuW.S., CerraF.B.. Pharmacokinetic analysis verifies P450 function during in vitro and in vivo application of a bioartificial liver.ASAIO J1993; 39: M252–6.
14.
StangeJ., MitznerS., StraußM.. Primary or established liver cells for a hybrid liver? Comparison of metabolic features.ASAIO J1995; 41: M310–5.
15.
NybergS.L., RemmelR.P., MannH.J., PeshwaM.V., HuW.A., CerraF.B.. Primary hepatocytes outperform Hep G2 cells as the source of biotransformation functions in a bioartificial liver.Ann Surg1994; 220(1): 59–67.
16.
SeglenP.O.. Preparation of isolated rat liver cells.Methods Cell Biol1976; 13: 29–83.
17.
RojkindM., GatmaitanZ., MackensenS., GiambroneM.A., PonceP., ReidL.M.. Connective tissue biomatrix: its isolation and utilization for long-term cultures of normal rat hepatocytes.J Cell Biol1980; 87(1): 255–63.
18.
MosmanT.. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.J Immunol Methods1983; 65: 55–63.
19.
MuracaM., BlanckaertN.. Identification and measurement by high-performance liquid chromatography of mono- and diester conjugates of bilirubin in human serum of healthy adults.Clin Chem1983; 29: 1767–71.
20.
FeveryJ., Van de VijverM., MichielsR., HeirweghK.P.M.. Comparison in different species of bilirubin IXa conjugates with the activities of hepatic and renal bilirubin IXa uridine diphosphate glycosyltransferase.Biochem J1997; 164: 737–46.
21.
te VeldeA.A., LadigesNCJJ, FlendrigL.M., ChamuleauRAFM. Functional activity of isolated pig hepatocytes in a bioartificial liver.J Hepatol1995; 23: 184–92.
22.
PatienceC., TakeuchiY., WeissR.A.. Infection of human cells by an endogenous retrovirus of pigs.Nature Med1997; 3: 282–6.
23.
van der LaanL.J.W., LocheyC., GriffethB.C.. Infection by porcine endogenous retrovirus after islet xenotransplantation in SCID mice.Nature2000; 407: 90–4.
24.
PitkinZ., MullonC.. Evidence of absence of porcine endogenous retrovirus (PERV) infection in patients treated with bioartificial liver support system.Int J Artif Organs1999; 23(9): 829–33.
25.
ParadisK., LangfordG., LongZ.. Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue.Science1999; 285: 1236–41.
26.
UchinoJ., MatsueH., TakahashiM.. A hybrid artificial liver system. Function of cultured monolyer pig hepatocytes in plasma from hepatic failure patients.ASAIO Trans1991; 37: M337–8.
27.
ButterworthR.F., GiguereJ.F., MichaudJ., LavoieJ., LayrarguesG.P.. Ammonia: a key factor in the pathogenesis of hepatic encephalopathy.Neurochem Pathol1987; 6(1-2): 1–12.
28.
KarpW.B.. Biochemical alterations in neonatal hyperbilirubinemia and bilirubin encephalopathy: a review.Pediatrics1979; 64: 361–8.
